Dexcom’s over-the-counter glucose monitor now available in the U.S.

JHVEPhoto/iStock Editorial via Getty Images Dexcom ( NASDAQ: DXCM ) said on Monday its over-the-counter glucose biosensor Stelo is now available for purchase in the U.S. Stelo is designed to help people, 18 years and older, with Type 2 diabetes who are not using insulin and those with prediabetes.

The U.S. Food and Drug Administration cleared the use of the device in March, making it the first continuous glucose monitor to be made available without a prescription.

The health regulator had noted the product should not be used by people with problematic low blood sugar levels, as it is not designed to alert users to the potentially dangerous condition. The device can now be purchased from Stelo.com at $99 for a single pack of two sensors, which could be used for up to 30 days.

Shares of Dexcom ( DXCM ) gained 0.72% premarket on Monday More on DexCom DexCom's Competitive Landscape: A Deep Dive Into The CGM Market DexCom Q2 Earnings: Traditional Market Overreaction DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures DexCom, Abbott to benefit from the multi-billion-dollar OTC continuous glucose market DexCom added to Raymond James analyst current favorite list.